KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Esperion Therapeutics (ESPR) Capital Expenditures (2016 - 2026)

Esperion Therapeutics filings provide 4 years of Capital Expenditures readings, the most recent being $167000.0 for Q3 2024.

On a quarterly basis, Capital Expenditures changed N/A to $167000.0 in Q3 2024 year-over-year; TTM through Jun 2025 was $167000.0, a 11.33% increase, with the full-year FY2024 number at $317000.0, changed N/A from a year prior.
Capital Expenditures hit $167000.0 in Q3 2024 for Esperion Therapeutics, up from $77000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $721000.0 in Q4 2020 to a low of -$628000.0 in Q3 2020.